Abstract
Intravesical drug therapy for neurogenic bladder is currently limited to oxybutynin where higher drug levels can be achieved with lower side effect profiles than via the oral route. The glycosaminoglycan layer over the urothelial barrier presents a major obstacle that prevents the efficient delivery of larger molecules into the tissue from the lumen. Current investigations are exploring the use of liposomes, nanoparticles, and electromotive gradients to enhance drug delivery. Investigational agents such as botulinum toxin, siRNA, and chemotherapeutic immunomodulators offer the potential for expanding the intravesical drug arsenal as the means for drug delivery improve.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
P. Krause, U. Fuhr, J. Schnitker, U. Albrecht, R. Stein, P. Rubenwolf, Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. J. Urol. 190(5), 1791–1797 (2013)
N.A. Williams, K.M. Lee, C.J. Allender, J.L. Bowen, M. Gumbleton, T. Harrah, et al., Investigating detrusor muscle concentrations of oxybutynin after intravesical delivery in an ex vivo porcine model. J. Pharm. Sci. 104(7), 2233–2240 (2015)
H. Madersbacher, G. Jilg, Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Paraplegia 29(2), 84–90 (1991)
H. Madersbacher, M. Knoll, Intravesical application of oxybutynine: mode of action in controlling detrusor hyperreflexia. Preliminary results. Eur. Urol. 28(4), 340–344 (1995)
A. Schroder, U. Albrecht, J. Schnitker, A. Reitz, R. Stein, Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi-center trial. Neurourol. Urodyn. 35(5), 582–588 (2016)
M. Chancellor, T. Boone, Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci. Ther. 18(2), 167–174 (2012)
M. Humblet, C. Verpoorten, M.H. Christiaens, H. Hirche, K. Jansen, G. Buyse, et al., Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourol. Urodyn. 34(4), 336–342 (2015)
M.O. Fraser, Y.C. Chuang, P. Tyagi, T. Yokoyama, N. Yoshimura, L. Huang, et al., Intravesical liposome administration – a novel treatment for hyperactive bladder in the rat. Urology 61(3), 656–663 (2003)
Y.C. Chuang, P. Tyagi, C.C. Huang, N. Yoshimura, M. Wu, J. Kaufman, et al., Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J. Urol. 182(2), 786–792 (2009)
H.C. Kuo, H.T. Liu, Y.C. Chuang, L.A. Birder, M.B. Chancellor, Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur. Urol. 65(6), 1117–1124 (2014)
Y.C. Chuang, J.H. Kaufmann, D.D. Chancellor, M.B. Chancellor, H.C. Kuo, Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J. Urol. 192(6), 1743–1749 (2014)
A.M. Kajbafzadeh, L. Montaser-Kouhsari, H. Ahmadi, M. Sotoudeh, Intravesical electromotive botulinum toxin type A administration: part I – experimental study. Urology 77(6), 1460–1464 (2011)
A.M. Kajbafzadeh, H. Ahmadi, L. Montaser-Kouhsari, L. Sharifi-Rad, F. Nejat, S. Bazargan-Hejazi, Intravesical electromotive botulinum toxin type A administration – part II: clinical application. Urology 77(2), 439–445 (2011)
P. Tyagi, M. Kashyap, H. Hensley, N. Yoshimura, Advances in intravesical therapy for urinary tract disorders. Expert Opin. Drug Deliv. 13(1), 71–84 (2016)
A. Giannantoni, S.M. Di Stasi, R.L. Stephen, V. Bini, E. Costantini, M. Porena, Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J. Urol. 172(1), 240–243 (2004)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Purves, J.T. (2023). Intravesical Drug Therapy. In: Liao, L., Madersbacher, H. (eds) Handbook of Neurourology. Springer, Singapore. https://doi.org/10.1007/978-981-99-1659-7_30
Download citation
DOI: https://doi.org/10.1007/978-981-99-1659-7_30
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-1658-0
Online ISBN: 978-981-99-1659-7
eBook Packages: MedicineReference Module Medicine